Answers are grounded in this paper and cite their sources.
Azacitidine and decitabine are hypomethylating agents that have dose‐dependent epigenetic and cytotoxic effects and are widely used in the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). In this review, we discuss the path to regulatory approval of azacitidine and decitabine, highlighting the substantial efforts that have been made to optimize the dosing schedule and administration of these drugs, including the development of new, oral formulations of both agents. We also review novel combination strategies that are being investigated in ongoing clinical trials for patients with MDS and AML, as well as efforts to expand the current indications of these agents.
No takes yet. Share an insight, caveat, or question.
Short et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: